As politicians race to replace Obamacare, researchers are racing to replace drugs that are on the verge of patent expiration. One opportunity points the way: biologics.
Teva Pharmaceuticals (TEVA) is an emerging leader in biologics, but its share price is getting unduly punished by the legislative circus in Washington, D.C. That spells a buying opportunity for contrarians.
